Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 188 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ 2012;344:e1086. [Ref.ID 92531]
22.Tiene citas relacionadas
Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med 2012;366:957-9. [Ref.ID 92495]
23.Tiene citas relacionadas Cita con resumen
Howard RH, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes CBC, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:914-24. [Ref.ID 92492]
24. Cita con resumen
Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc 2011;59:2069-76. [Ref.ID 91576]
25. Cita con resumen
Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011;59:1019-31. [Ref.ID 90768]
26.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-31. [Ref.ID 90421]
27. Cita con resumen
Anónimo. NICE recommends Alzheimer's drugs for mild disease. BMJ 2011;342:678. [Ref.ID 90340]
29. Cita con resumen
Anónimo. Syndrome des jambes sans repos d'origine médicamenteuse. Prescrire 2010;30:270-2. [Ref.ID 88321]
30. Cita con resumen
31.Enlace a cita original
Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-8. [Ref.ID 86355]
32. Cita con resumen
Burns A, Iliffe S. Alzheimer's disease. BMJ 2009;338:467-71. [Ref.ID 85335]
33. Cita con resumen
Gilstad JR, Finucane TE. Results, rhetoric, and randomized trials: the case of donepezil. J Am Geriatr Soc 2008;56:1556-62. [Ref.ID 82938]
34. Cita con resumen
Dyer C. Court rules that NICE procedure on dementia drugs was unfair. BMJ 2008;336:1035. [Ref.ID 82863]
35. Cita con resumen
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-97. [Ref.ID 82315]
36. Cita con resumen
Anónimo. Pfizer lifts outlook as Lyrica and Chantix prop up sales in 2007. Scrip 2008;3331:9. [Ref.ID 82104]
37.Tiene citas relacionadas
Yaffe K. Treatment of neuropsychiatric symptoms in patients with dementia. N Engl J Med 2007;357:1441-3. [Ref.ID 81143]
38.Tiene citas relacionadas Cita con resumen
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M, for the CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-92. [Ref.ID 81139]
39. Cita con resumen
Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia. BMJ 2007;335:557. [Ref.ID 81089]
40.
Dyer O. High Court backs NICE's decision on Alzheimer's drugs. BMJ 2007;335:319. [Ref.ID 80897]
Seleccionar todas
 
<< anterior 21 a 40 de 188 siguiente >>